{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:24:20Z","timestamp":1772119460554,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National Cancer Center Research and Development Fund","award":["23-A-22"],"award-info":[{"award-number":["23-A-22"]}]},{"name":"the National Cancer Center Research and Development Fund","award":["26-A-4"],"award-info":[{"award-number":["26-A-4"]}]},{"name":"the National Cancer Center Research and Development Fund","award":["29-A-3"],"award-info":[{"award-number":["29-A-3"]}]},{"name":"the National Cancer Center Research and Development Fund","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]},{"name":"the National Cancer Center Research and Development Fund","award":["2023-J-03"],"award-info":[{"award-number":["2023-J-03"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ck0106350"],"award-info":[{"award-number":["JP19ck0106350"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Grant-in-Aid for Clinical Cancer Research rom the Ministry of Health, Labor, and Welfare of Japan","award":["H22-ganrinsho-ippan-013"],"award-info":[{"award-number":["H22-ganrinsho-ippan-013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10147-025-02834-x","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T04:28:05Z","timestamp":1753331285000},"page":"2053-2062","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of clinical features by primary site in patients with biliary tract cancer who received gemcitabine-based chemotherapy: an exploratory analysis of JCOG1113"],"prefix":"10.1007","volume":"30","clinical-trial-number":[{"clinical-trial-number":"umin000010667","registry":"10.18810\/umin-japan"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7362-5550","authenticated-orcid":false,"given":"Yuko","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junki","family":"Mizusawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Imaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruo","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Todaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobumasa","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohei","family":"Satoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Tobimatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Katanuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"10272","key":"2834_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B et al (2021) Biliary tract cancer. Lancet 397(10272):428\u2013444","journal-title":"Lancet"},{"issue":"2","key":"2834_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J et al (2023) Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(2):127\u2013140","journal-title":"Ann Oncol"},{"issue":"14","key":"2834_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273\u20131281","journal-title":"N Engl J Med"},{"key":"2834_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz402","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J et al (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdz402","journal-title":"Ann Oncol"},{"issue":"4","key":"2834_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.21037\/cco.2019.08.13","volume":"8","author":"MA Schmidt","year":"2019","unstructured":"Schmidt MA, Marcano-Bonilla L, Roberts LR (2019) Gallbladder cancer: epidemiology and genetic risk associations. Chin Clin Oncol 8(4):31","journal-title":"Chin Clin Oncol"},{"key":"2834_CR6","doi-asserted-by":"publisher","first-page":"103328","DOI":"10.1016\/j.critrevonc.2021.103328","volume":"163","author":"AA Azizi","year":"2021","unstructured":"Azizi AA, Lamarca A, McNamara MG et al (2021) Chemotherapy for advanced gallbladder cancer (GBC): a systematic review and meta-analysis. Crit Rev Oncol Hematol 163:103328","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2834_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jhbp.314","volume":"23","author":"S Ishihara","year":"2016","unstructured":"Ishihara S, Horiguchi A, Miyakawa S et al (2016) Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci 23(3):149\u2013157","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"1","key":"2834_CR8","doi-asserted-by":"publisher","first-page":"10206","DOI":"10.1038\/s41598-022-13605-3","volume":"12","author":"MJ Kang","year":"2022","unstructured":"Kang MJ, Lim J, Han SS et al (2022) Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study. Sci Rep 12(1):10206","journal-title":"Sci Rep"},{"issue":"6","key":"2834_CR9","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1080\/00365521.2019.1619827","volume":"54","author":"BG Song","year":"2019","unstructured":"Song BG, Park JK, Kim HS et al (2019) Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location. Scand J Gastroenterol 54(6):740\u2013745","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"2834_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/CEJ.0000000000000260","volume":"26","author":"T Makiuchi","year":"2017","unstructured":"Makiuchi T, Sobue T, Kitamura T et al (2017) Reproductive factors and gallbladder\/bile duct cancer: a population-based cohort study in Japan. Eur J Cancer Prev 26(4):292\u2013300","journal-title":"Eur J Cancer Prev"},{"issue":"2","key":"2834_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/ijc.34916","volume":"155","author":"A Shin","year":"2024","unstructured":"Shin A, Cho S, Abe SK et al (2024) Association of female reproductive and hormonal factors with gallbladder cancer risk in Asia: a pooled analysis of the Asia Cohort Consortium. Int J Cancer 155(2):240\u2013250","journal-title":"Int J Cancer"},{"issue":"4","key":"2834_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jhep.2020.04.046","volume":"73","author":"SS Jackson","year":"2020","unstructured":"Jackson SS, Adami HO, Andreotti G et al (2020) Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project. J Hepatol 73(4):863\u2013872","journal-title":"J Hepatol"},{"issue":"19\u201320","key":"2834_CR13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10354-006-0346-x","volume":"156","author":"G Novacek","year":"2006","unstructured":"Novacek G (2006) Gender and gallstone disease. Wien Med Wochenschr 156(19\u201320):527\u2013533","journal-title":"Wien Med Wochenschr"},{"issue":"1","key":"2834_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00534-007-1278-6","volume":"15","author":"K Tsukada","year":"2008","unstructured":"Tsukada K, Takada T, Miyazaki M et al (2008) Diagnosis of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 15(1):31\u201340","journal-title":"J Hepatobiliary Pancreat Surg"},{"issue":"29","key":"2834_CR15","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.2174\/0929867327666200123090153","volume":"27","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Frizziero M, McNamara MG et al (2020) Clinical and translational research challenges in biliary tract cancers. Curr Med Chem 27(29):4756\u20134777","journal-title":"Curr Med Chem"},{"issue":"2","key":"2834_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.suc.2014.01.009","volume":"94","author":"JA Wernberg","year":"2014","unstructured":"Wernberg JA, Lucarelli DD (2014) Gallbladder cancer. Surg Clin North Am 94(2):343\u2013360","journal-title":"Surg Clin North Am"},{"issue":"22","key":"2834_CR17","doi-asserted-by":"publisher","first-page":"e33656","DOI":"10.1097\/MD.0000000000033656","volume":"102","author":"M Utsumi","year":"2023","unstructured":"Utsumi M, Inagaki M, Kitada K et al (2023) Preoperative C-reactive protein-to-albumin ratio as a prognostic factor in biliary tract cancer: a systematic review and meta-analysis. Medicine (Baltimore) 102(22):e33656","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2834_CR18","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.4143\/crt.2016.538","volume":"49","author":"HS Park","year":"2017","unstructured":"Park HS, Park JS, Chun YJ et al (2017) Prognostic factors and scoring model for survival in metastatic biliary tract cancer. Cancer Res Treat 49(4):1127\u20131139","journal-title":"Cancer Res Treat"},{"issue":"1","key":"2834_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00280-017-3353-2","volume":"80","author":"BJ Kim","year":"2017","unstructured":"Kim BJ, Hyung J, Yoo C et al (2017) Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol 80(1):209\u2013215","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2834_CR20","doi-asserted-by":"publisher","first-page":"21548","DOI":"10.1038\/s41598-023-48889-6","volume":"13","author":"H Imaoka","year":"2023","unstructured":"Imaoka H, Ikeda M, Nomura S et al (2023) Development of a nomogram to predict survival in advanced biliary tract cancer. Sci Rep 13(1):21548","journal-title":"Sci Rep"},{"issue":"6","key":"2834_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"DY Oh","year":"2022","unstructured":"Oh DY, Lee KH, Lee DW et al (2022) Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol 7(6):522\u2013532","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10391","key":"2834_CR22","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10391):1853\u20131865","journal-title":"Lancet"},{"key":"2834_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003214","author":"X Chen","year":"2021","unstructured":"Chen X, Wang D, Liu J et al (2021) Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003214","journal-title":"J Immunother Cancer"},{"issue":"7","key":"2834_CR24","first-page":"4990","volume":"14","author":"L Guo","year":"2022","unstructured":"Guo L, Zhou F, Liu H et al (2022) Genomic mutation characteristics and prognosis of biliary tract cancer. Am J Transl Res 14(7):4990\u20135002","journal-title":"Am J Transl Res"},{"key":"2834_CR25","doi-asserted-by":"publisher","first-page":"988527","DOI":"10.3389\/fonc.2022.988527","volume":"12","author":"K Takada","year":"2022","unstructured":"Takada K, Kubo T, Kikuchi J et al (2022) Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: a prospective multicenter study. Front Oncol 12:988527","journal-title":"Front Oncol"},{"issue":"1","key":"2834_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40164-023-00470-7","volume":"13","author":"C Astier","year":"2024","unstructured":"Astier C, Ngo C, Colmet-Daage L et al (2024) Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA. Exp Hematol Oncol 13(1):2","journal-title":"Exp Hematol Oncol"},{"issue":"23","key":"2834_CR27","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1158\/1078-0432.CCR-23-1926","volume":"29","author":"TY Tang","year":"2023","unstructured":"Tang TY, Nichetti F, Kaplan B et al (2023) Comparative genomic analysis and clinical outcomes of BRAF-mutated advanced biliary tract cancers. Clin Cancer Res 29(23):4853\u20134862","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2834_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103630","volume":"9","author":"IA Mavroeidi","year":"2024","unstructured":"Mavroeidi IA, Burghofer J, Kalbourtzis S et al (2024) Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity. ESMO Open 9(8):103630","journal-title":"ESMO Open"},{"issue":"10","key":"2834_CR29","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.3390\/curroncol29100573","volume":"29","author":"M Kanai","year":"2022","unstructured":"Kanai M (2022) Current clinical practice of precision medicine using comprehensive genomic profiling tests in biliary tract cancer in Japan. Curr Oncol 29(10):7272\u20137284","journal-title":"Curr Oncol"},{"issue":"9","key":"2834_CR30","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Lassen U, Elez E et al (2020) Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 21(9):1234\u20131243","journal-title":"Lancet Oncol"},{"issue":"30","key":"2834_CR31","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.2217\/fon-2020-0429","volume":"16","author":"TS Bekaii-Saab","year":"2020","unstructured":"Bekaii-Saab TS, Valle JW, Van Cutsem E et al (2020) FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol 16(30):2385\u20132399","journal-title":"Future Oncol"},{"issue":"11","key":"2834_CR32","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM et al (2021) Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical clarIDHy trial. JAMA Oncol 7(11):1669\u20131677","journal-title":"JAMA Oncol"},{"issue":"9","key":"2834_CR33","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","volume":"22","author":"M Javle","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS et al (2021) Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 22(9):1290\u20131300","journal-title":"Lancet Oncol"},{"issue":"3","key":"2834_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A et al (2023) Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med 388(3):228\u2013239","journal-title":"N Engl J Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02834-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02834-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02834-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T07:38:00Z","timestamp":1758872280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02834-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2834"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02834-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5483078\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.S. reports research fundings from Chugai Pharmaceutical Co., Ltd. M.I. reports consulting fees from AstraZeneca K.K. and MSD K.K., honoraria from AstraZeneca K.K., Guardant Health Japan Corp., Incyte Biosciences Japan G.K., MSD K.K. and Taiho Pharmaceutical Co., Ltd., and research fundings from AstraZeneca K.K., Boehringer Ingelheim Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, J-Pharma Co., Ltd., Merck Biopharma Co., Ltd. and Ono Pharmaceutical Co., Ltd. J.M. reports honoraria from Chugai Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co., Ltd., and his spouse is an employee of Pfizer Japan Inc. C.M. reports honoraria from AstraZeneca K.K., Eisai Co., Ltd., Guardant Health Japan Corp., MSD K.K., Myriad Genetic G.K., Novartis Pharma K.K., Nihon Servier Co., Ltd., Taiho Pharmaceutical Co., Ltd., Toray Industries, Inc., and Yakult Honsha Co., Ltd., and research fundings from AstraZeneca K.K., Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., J-Pharma Co., Ltd., Merck Biopharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Yakult Honsha Co., Ltd. T.O. reports grants from AstraZeneca K.K., Bristol Myers Squibb K.K., Chiome Bioscience Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Incyte Biosciences Japan G.K., MSD K.K., Novartis Pharma K.K., Syneos Health Clinical K.K. and Sysmex Corp., consulting fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., FUJIFILM Toyama Chemical Co., Ltd., Nihon Servier Co., Ltd., Novartis Pharma K.K. and Ono Pharmaceutical Co., Ltd., honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Johnson & Johnson, Myriad Genetic G.K., Nihon Servier Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Syneos Health Clinical K.K., Taiho Pharmaceutical Co., Ltd. and Yakult Honsha Co., Ltd. S.K. reports honoraria from AstraZeneca K.K. and MSD K.K. H.I. reports honoraria from AstraZeneca K.K., Boston Scientific Corp., Kaneka Medix Corp., Nihon Servier Co., Ltd., Novartis Pharma K.K., SB-KAWASUMI LABORATORIES, INC. and Yakult Honsha Co., Ltd., fees for promotional materials from Medico\u2019s Hirata Inc., research fundings from Boehringer Ingelheim Co., Ltd., Nihon Servier Co., Ltd., Novartis Pharma K.K. and Ono Pharmaceutical Co., Ltd., and he is a participant on an advisory board of Nihon Servier Co., Ltd. T.T. reports honoraria from AstraZeneca K.K. and Chugai Pharmaceutical Co., Ltd. N.O. reports honoraria from AstraZeneca K.K. A.T. reports honoraria from AstraZeneca K.K., Nihon Servier Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Teijin Pharma, Ltd. and Yakult Honsha Co., Ltd. S.S. reports research fundings from AstraZeneca K.K., Delta-Fly Pharma, Inc., Incyte Biosciences Japan G.K. and Nihon Servier Co., Ltd. N.M. reports research fundings from AstraZeneca K.K., Boehringer Ingelheim Co., Ltd., Incyte Biosciences Japan G.K., MSD K.K., Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc. and Seagen Inc. S.S. reports research fundings from Amino Up Co., Ltd., Boston Scientific Corp. and Nihon Servier Co., Ltd. M.O. reports honoraria from MSD K.K., Nihon Servier Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd. and Yakult Honsha Co., Ltd. M.U. reports honoraria from Taiho Pharmaceutical Co., Ltd. and Yakult Honsha Co., Ltd., and fundings from Taiho Pharmaceutical Co., Ltd. The other authors have nothing to declare for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"JCOG1113 was conducted in accordance with the 1964 Declaration of Helsinki, its later amendments and Japanese Ethical Guidelines for Clinical Research, and the study protocol was approved by the institutional review board of each participating institution. The written informed consent was obtained from all participants of JCOG1113.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval statement, patient consent statement, and permission to reproduce material from other sources"}}]}}